Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide and Duvalisib in R/R PTCL
NCT06151106Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and duvelisib in peripheral T-cell lymphoma (PTCL) and Natural killer T-cell lymphoma (NKTL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: Overall Response Rate at 27 months and Complete Response Rate at 27 months. Started Nov 2023; status: recruiting.
02
Drugs
tucidinostatduvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)Natural killer T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on NCT06151106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151106.